TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026)
TerrAscend's (TSNDF) quarterly Income from Continuing Operations came in at 6829000.0 in Q1 2026, up 10.91% year-on-year from 6157426.77 in Q1 2025, and down 1233.79% on a QoQ basis from 512000.0 in Q4 2025.
TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Income from Continuing Operations data on file, last reported at 6829000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 10.91% year-over-year to 6829000.0 in Q1 2026; TTM through Mar 2026 was 23654000.0, a 352.69% decrease from a year earlier, with the FY2025 full-year figure at 24489000.0, down 412.76% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6829000.0, down from 512000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for TSNDF reached as high as 39147000.0 in Q4 2024 and fell as low as 300561000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 21773117.65 across 5 years, with a median of 7665000.0 in 2025.
- Across the five-year window, Income from Continuing Operations slumped 638.3% in 2022 and jumped 1410.88% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 5666000.0 in 2022, then surged by 145.73% to 2591000.0 in 2023, then soared by 1410.88% to 39147000.0 in 2024, then tumbled by 101.31% to 512000.0 in 2025, then plunged by 1233.79% to 6829000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 6829000.0 in Q1 2026, 512000.0 in Q4 2025, and 9907000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | -6.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.83 Mn |
| Dec 31, 2025 | -512,000.00 |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -7.67 Mn |
| Dec 31, 2024 | 39.15 Mn |
| Sep 30, 2024 | -15.84 Mn |
| Jun 30, 2024 | -6.29 Mn |
| Mar 31, 2024 | -14.85 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | -8.44 Mn |
| Jun 30, 2023 | -12.86 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -300.56 Mn |
| Jun 30, 2022 | 16.86 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 55.84 Mn |
| Jun 30, 2021 | -29.66 Mn |